Furthermore, no correlation was observed between anti‐FIRΔexon2 Abs and the seven tumor markers (anti‐CFAP70, anti‐KARS, anti‐SNX15, anti‐SOHLH1 Abs, CEA, CA19‐9, and anti‐p53 Abs; Figure 2), indicating that anti‐FIRΔexon2 Abs is an independent marker for patients with CRC. This evidence concerns the gene TP53 and neoplasm.